in human lymphoid malignancy and results in bcl-2 overexpression. bcl-2 blocks apoptosis and constitutes the initial member of a new catagory of oncogenes, ie, regulators of cell death. Bc/-2-/g transgenic mice develop follicular hyperplasia and progress to malignant B-cell lymphoma. To assess the oncogenic potential of bcl-2 in the T-cell lineage, a cohort of 68 /cP"bcl-Z transgenic mice and 56 control littermates were monitored for signs of malignancy over a 24-month period. Eighteen (26%) /cP"bc/-2 mice developed diffuse, predominantly largecell lymphomas at a mean age of 18 months.
cl-2 WAS DISCOVERED by cloning the t( 14; 18)(q32;q21) chromosomal breakpoint characteristic of human follicular B-cell lymph~ma."~ Approximately 85% of follicular and 20% of diffuse B-cell lymphomas display the t(14; 18). 4 bcl-2 has the unique role of extending cell survival rather than promoting cell proliferation. Transgenic mice bearing a bcl-2-Ig minigene uniformally develop a polyclonal follicular hyperplasia with a fourfold expansion of mature resting peripheral B cells.' After a substantial latency period (>9 months), approximately 15% of these transgenic mice develop monoclonal diffuse aggressive lymphomas. 6 The bcl-2-Ig transgenic mouse model proves that extended cell survival is oncogenic within the B-cell lineage. The long latency period, histologic conversion, and progression from polyclonality to monoclonality implicate secondary genetic changes as part of lymphomagenesis. Approximately half of the high-grade B-cell lymphomas show a c-myc translocation! Ep-bcl-2 transgenic mice independently derived also show an increased incidence of B-cell lymphoma, confirming the oncogenic potential of bcl-2.' Bcl-Zdeficient mice argue that bcl-2's primary role in the lymphoid system is the maintainance of horneo~tasis.~~ For example, in the thymus, bcl-2 is normally upregulated at the CD4'CDS' stage during positive selection" and mature peripheral T cells retain substantial levels of bcl-2 protein.
Bcl-2 homozygous-deficient mice initially show normal lymphoid differentiation; however, with time, both primary and secondary lymphoid organs undergo massive apoptosis leading to a marked lymph~penia.~.~
The present study addresses the oncogenic potential of bcl-2 beyond B cells, within the T-cell lineage. Translocations involving chromosome segment 18q21 are uncommon in human T-cell IeukemiaAymphoma, and bcl-2 protein levels do not appear to be substantially increased in most Tcell neoplasms.".'* Thus, within the context of T-cell neoplasia, the oncogenic impact of extended cell survival remains uncertain. Consequently, we undertook a longitudinal study of 1ckPr-bcl-2 transgenic mice that overexpress bcl-2 within the thymus as well as in peripheral T cells. We report that IcP-bcl-2 transgenic mice show a marked incidence of peripheral T-cell lymphoma. In contrast, only one nontransgenic control mouse developed lymphoma. CD3 surface expression and clonal T-cell receptor / 3 rearrangements support the T-lineage classification of these neoplasms. /ckp"bcl"enforced lymphomas are predominantly CDI+CDI-, consistent with a mature peripheral T-cell phenotype. These data provide support for the thesis that violation of homeostasis through the repression of cell death can be a primary mechanism of tumorigenesis in multiple lineages. Western blot analysis. Splenic T cells from mice were purified (>95% CD3') by negative selection using MoAbs and magnetic beads." Western blot analysis of 35 pg cytoplasmic protein per lane was performed using the bcI-2 species-specific (6C8, antihuman bcl-2 and 3F1 l, and antimouse bcl-2) MoAbs as de~cribed?'~ Blots were developed by ECL (Amersham, Arlington Heights, E).
B MATERIALS AND METHODS

Mice
RESULTS
Zckpr-bcl-2 transgenic mice express (human) bcl-2 in cortical and medullary thymocytes as well as in peripheral T cells. As previously noted," Ickp' transgene expression is partially downregulated during T-cell maturation, as indicated by a lower fluorescence intensity of mature peripheral T cells (versus thymocytes) using the 6C8 antibody specific 
-cell lysates from individual mice is presented (inset). bcl-2 homozygous-deficient (bcI-Z-/-), heterozygous-deficient (bcl-2+/-), and wild-type littermates (bcl-2+/+1 have been previously described?
for human bcl-2 (Fig l) . Peripheral T cells from Ickpr'-hcl-2 mice retain substantially higher levels of bcl-2 when compared with T cells from Bcl-2"' animals, as determined by Western blot (Fig I , inset) . Neither B cells nor other hematopoietic lineages express detectable transgenic bcl-2 protein, consistent with the lineage-restricted expression of the Ick pr~moter.'~ Thymocytes and peripheral T cells from /ckP'-hcl-2 mice are resistant to glucocorticoid-, b-irradiation-, and anti-CD3-induced cell death.'? At 12 months of age, IckPr-hcl-2 animals have a threefold to fourfold increase in mature T cells, as monitored by absolute splenic T-cell counts (IckPr-hc/-2 [n = 81, 83 ? 20 X IO" compared with control littermates [n = 41, 25 2 2.1 X 10'). To assess the oncogenic potential of bcl-2 within the T-cell lineage, a cohort of 68 IckPr-hc/-2 transgenic mice and 56 control (nontransgenic) littermates were monitored for signs of adenopathy and ill health for up to 24 months of age. Of 68 transgenic mice, 18 developed lymphoma at a mean age of 18 months (range, 12 to 23 months; Fig 2) . In contrast, only 1 of 56 control littermates developed lymphoma at 19 months of age. In addition, 4 additional tumors were found within the entire tumor watch cohort (2 hepatocellular carcinomas, 1 high-grade sarcoma, and 1 intraductal breast carcinoma; Table l). No latent tumors were found when healthy animals that survived to 24 months of age were killed.
Histologic analysis shows that most (15 of 18) lymphomas from /ckP'-hc/-2 mice were large-cell lymphomas (Fig 3A) . with several showing immunoblastic features (Fig 3B) . The remaining 3 were classified as diffuse small lymphocytic lymphomas (Fig 3C through E) . The single lymphoma discovered in the control group was a diffuse large-cell lymphoma obtained from a mediastinal node. Most cases presented as a rapidly expanding abdominal mass within the mesenteric lymph nodes; however, there were several instances in which a mediastinal or cervical node appeared to be the primary site. The diffuse nature of lymphomas from IckPr-hcl-2 mice is reflected in the frequent finding of splenomegaly, ascites, and extranodal involvement (liver. testis, skeletal muscle, and lung) evident in most animals (Fig 3D and E) .
Lymphomas were further characterized by flow cytometry and antigen receptor rearrangements for lineage classification. The T-cell origin of all lymphomas studied was apparent by an intense staining with anti-CD3 antibody as well as an absence of reactivity with the B-cell-specific antibody to B220 (data not shown). Further analysis indicated that these neoplasms were predominantly of the CD4-CD8-subset; in fact, only 1 tumor (7-16) was phenotyped as CD4-CD8' (Table l) . In addition, the lymphomas were judged to be clonal, as determined by TCR 0 rearrangement on Southern blot analysis (Fig 4) . Ig heavy chain genes remained in the germline configuration, consistent with their proposed T-cell origin (data not shown). No c-myc gene rearrangements were noted among the T-cell lymphomas tested ( Table 1 ) . The founder line is designated by the first number in the series of each mouse. Abbreviations: LCL-I, large-cell lymphoma, immunoblastic; LCL, large-cell lymphoma: SLL, small lymphocytic lymphoma: MLN, mesenteric lymph node; MedLN, mediastinal lymph node; CLN, cervical lymph node; spl, spleen: C, clonal rearrangement present; G, germline configuration. *Lymphomas were classified by flow cytornetry as belonging to either the CD4 T-cetl subset 1CD3+CD4'CD8-) or CD8 T-celi subset (CD3+CD4-CD8'). In addition, lymphomas from IckP'-bcl-2 mice stained positive with 6C8 MoAb (antihuman bcl-2) in Western blotting assays and flow cytometry. the transgenic mouse model (as well as in human lymphoma) implicate secondary somatic changes required for tumorigenesis. Indeed, deregulated c-rnyc expression is frequently found in malignant B-cell lymphomas from these transgenic
In the present study, we sought to determine the oncogenic potential of bcl-2 in a different lineage. We find that mice bearing the lckP'-bcf-2 transgene develop T-cell hyperplasia followed by diffuse malignant T-cell lymphoma, indicating that repression of cell death can be a primary mechanism of tumorigenesis in this lineage as well.
In many respects, lymphomas from 1ckP"bcZ-2 mice are similar to the B-cell lymphomas previously described from bcl-2-Zg mice.6 In general, these malignancies are best classified as diffuse, large-cell non-Hodgkin's lymphomas. In the current study, 15 of the 18 neoplasms from ZckPr-bcl-2 mice were either large-cell or mixed small lymphocytic and largecell lymphomas. The large-cell lymphomas showed a range of histologic appearances with some showing a vaguely monocytoid (Fig 3A) or histiocytic appearance with pale cytoplasm similar to that seen in human peripheral T-cell lymphomas.I8 Two other lymphomas showed a high mitotic rate with features best classified as immunoblastic type ( Fig  3B) . Phenotypically, both B-and T-cell lymphomas appear to be derived from mature peripheral lymphocytes that accumulate in the secondary lymphoid organs within either transgenic line. Interestingly, the mesenteric nodes are the most common primary site of involvement. A second feature is the substantial latency period required for histologic conversion and transformation. However, it appears that T-cell lymphomas require a somewhat longer latency period because the mean age at diagnosis was 18 months (range, I2 to 23 months); in contrast, the mean age of bcl-2-Zg mice harboring malignant lymphoma was 13.5 months (range, 7 to 21 months). Perhaps this finding reflects an inherent difference of B cells when confronted with somatic changes that alter cellular proliferation. For example, c -r n y~'~-~' and cyclin DI/~CZ-I/PRAD-~~~-~~ overexpression are frequent gain of function mutations that result in a proliferative advantage within B-cell lymphomas. In our study, we were unable to find any evidence of either c-rnyc or cyclin D1 overexpression in T-cell lymphomas from ZckP' -bcZ-2 mice (data not shown). Thus, it appears that secondary genetic alterations that accompany lymphomagenesis are not necessarily common to B and T cells.
It is clear that disruption of apoptotic pathways either through gain of function (ie, bcZ-2) or loss of function mutations (ie, p53) can have a profound impact on cancer susceptibility. Recent evidence suggests that p53 is a required component of an apoptotic pathway used in response to DNA p53-deficient mice are predisposed to malig- 
nancy. most notably T-cell
In this study, enforced bcl-2 dramatically increased the incidence of peripheral T-cell lymphoma. Thus, increasing the resistance to apoptosis in B and T lymphocytes appears to make them susceptible to genetic alterations that may normally lead to cell death. Extended cell survival may be particularly oncogenic to long-lived lymphocytes due to their capacity to re-enter the cell cycle with antigen stimulation. This gain of function study with bcl-2 argues that, when apoptotic death programs are repressed, extended cell survival clearly renders a cell susceptible to transformation.
